212 related articles for article (PubMed ID: 22143157)
1. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status.
Deeg HJ; Bartenstein M
Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):31-41. PubMed ID: 22143157
[TBL] [Abstract][Full Text] [Related]
2. Current status of allogeneic hematopoietic cell transplantation for MDS.
Xu F; Deeg HJ
Curr Pharm Des; 2012; 18(22):3215-21. PubMed ID: 22571701
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic cell transplantation from alternative donors in children with myelodysplastic syndrome: is that an alternative?
Kalwak K; Wójcik D; Gorczyńska E; Toporski J; Turkiewicz D; Slociak M; Ussowicz M; Pajdosz K; Socha P; Chybicka A
Transplant Proc; 2004 Jun; 36(5):1574-7. PubMed ID: 15251388
[TBL] [Abstract][Full Text] [Related]
6. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
7. Hemopoietic cell transplantation for the myelodysplastic syndromes.
Scott BL; Deeg HJ
Arch Immunol Ther Exp (Warsz); 2005; 53(4):297-307. PubMed ID: 16088314
[TBL] [Abstract][Full Text] [Related]
8. Transplant strategies for patients with myelodysplastic syndromes.
Deeg HJ
Curr Opin Hematol; 2006 Mar; 13(2):61-6. PubMed ID: 16456370
[TBL] [Abstract][Full Text] [Related]
9. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?
Gyurkocza B; Deeg HJ
Blood Rev; 2012 Nov; 26(6):247-54. PubMed ID: 22981712
[TBL] [Abstract][Full Text] [Related]
11. The evolution of hematopoietic SCT in myelodysplastic syndrome.
Kindwall-Keller T; Isola LM
Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
[TBL] [Abstract][Full Text] [Related]
12. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndromes.
Platzbecker U
Semin Hematol; 2012 Oct; 49(4):342-9. PubMed ID: 23079064
[TBL] [Abstract][Full Text] [Related]
14. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.
Valcárcel D; Martino R
Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468
[TBL] [Abstract][Full Text] [Related]
15. Autologous and allogeneic stem cell transplantation for myelodysplastic syndrome.
de Witte T; Oosterveld M; Muus P
Blood Rev; 2007 Jan; 21(1):49-59. PubMed ID: 16822600
[TBL] [Abstract][Full Text] [Related]
16. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.
Demuynck H; Verhoef GE; Zachee P; Emonds MP; van der Schueren E; van den Berghe H; Vandenberghe P; Casteels-Van Daele M; Boogaerts MA
Bone Marrow Transplant; 1996 May; 17(5):745-51. PubMed ID: 8733692
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.
de Lima M; Giralt S
Semin Hematol; 2006 Apr; 43(2):107-17. PubMed ID: 16616044
[TBL] [Abstract][Full Text] [Related]
18. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.
Mori T; Aisa Y; Yokoyama A; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Kato J; Watanabe R; Takayama N; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2007 Feb; 39(4):217-21. PubMed ID: 17220902
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning.
Servais S; Baron F; Beguin Y
Transfus Apher Sci; 2011 Apr; 44(2):205-10. PubMed ID: 21345734
[TBL] [Abstract][Full Text] [Related]
20. Haematopoietic transplants combining a single unrelated cord blood unit and mobilized haematopoietic stem cells from an adult HLA-mismatched third party donor. Comparable results to transplants from HLA-identical related donors in adults with acute leukaemia and myelodysplastic syndromes.
Sebrango A; Vicuña I; de Laiglesia A; Millán I; Bautista G; Martín-Donaire T; Regidor C; Cabrera R; Fernandez MN
Best Pract Res Clin Haematol; 2010 Jun; 23(2):259-74. PubMed ID: 20837338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]